| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5882917 | Clinical Lymphoma Myeloma and Leukemia | 2016 | 6 Pages |
Abstract
WT1 gene mutations are a predictor indicator of a poor prognosis factor in CN-AML patients. It is recommended that WT1 gene mutations be included in the molecular testing panel in order to better diagnose and confirm their prognostic significance for better management and treatment strategy.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Gholamreza Toogeh, Mani Ramzi, Mohammad Faranoush, Naser Amirizadeh, Sezaneh Haghpanah, Mohammad Moghadam, Nader Cohan,